Information Provided By:
News For CUDA;CATS;CYBR;EXAR;GEN;HQY;KND;KFX;PN;DOC;PFPT;SEM From the Last 2 Days
CYBR
DOC
Apr 22, 2024 | 07:00 EDT
Mizuho resumed coverage of Healthpeak Properties with a Buy rating and $22 price target. The shares have underperformed healthcare real estate investment trusts year-to-date as investors remain concerned about capital allocation and value creation, challenging fundamentals in life sciences and limited growth opportunities in the company's medical office segment, the analyst tells investors in a research note. However, the firm sees several catalysts during the next few quarters for Healthpeak to re-rate, including selling assets and buying back stock, and an inflection in life science fundamentals in the second half of 2024.
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.